Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy

References

• Lee W M. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733–1745
   PubMed Web of Science ®Google Scholar
• Ustün C, Koç H, Karayalcin S, Akyol G, Gürman G, Ilhan O, et al. Hepatitis B virus infection in allogenic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 289–296
   PubMed Web of Science ®Google Scholar
• Mindikoglu A L, Regev A, Schiff E R. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076
   PubMed Web of Science ®Google Scholar
• Lim L L, Wai C T, Lee Y M, Kong H L, Lim R, Koay E, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16: 1939–1944
   PubMed Web of Science ®Google Scholar
• Yeo W, Lam K C, Zee B, Chan P SK, Mo F KF, Ho W M, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661–1666
   PubMed Web of Science ®Google Scholar
• Fattovich G, Brollo L, Alberti A, Realdi G, Pontisso P, Giustina G, et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990; 10: 141–146
   PubMedGoogle Scholar
• Tong M J, Sampliner R E, Govindarajan S, Co R L. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology 1987; 7: 713–718
   PubMed Web of Science ®Google Scholar
• Davis G L, Hoofnagle J H. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 1985; 102: 762–765
   PubMed Web of Science ®Google Scholar
• Davis G L, Hoofnagle J H, Waggoner J G. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230–235
   PubMed Web of Science ®Google Scholar
• Lok A S, Liang R H, Chiu E K, Wong K L, Chan T K, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182–188
   PubMed Web of Science ®Google Scholar
• Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer O, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis 2005; 58: 15–19
   PubMed Web of Science ®Google Scholar
• Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with Hepatitis B reactivation. Br J Haematol 2000; 108: 394–396
   PubMed Web of Science ®Google Scholar
• Persico M, De Marino F, Russo G D, Morante A, Rotoli B, Torella R, et al. Efficiency of lamivudine to prevent hepatitis reactivation in hepatitis B virus infected patients treated for non-Hodgkin Lymphoma. Blood 2002; 99: 724–725
   PubMed Web of Science ®Google Scholar
• Shibolet O, Iian Y, Gillis S, Hubert A, Shouval D, Safadi R, et al. Lamivudine therapy for prevention of immunosuppresive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391–396
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58–62
   PubMed Web of Science ®Google Scholar
• Kohrt H E, Ouyang D L, Keeffe E B. Systematic review: lamivudine prophylaxis for chemotherapy induced reactivation of chronic hepatitis B virus infection aliment. Pharmacol Ther 2006; 24: 1003
   Web of Science ®Google Scholar
• Yeo W, Chan P KS, Ho W M, Zee B, Lam K C, Lei K IK, et al. Lamivudine for the Prevention of hepatitis B virus reactivation in hepatitis B antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927–934
   PubMed Web of Science ®Google Scholar
• Hoofnagle J H, Dusheiko G M, Schafer D F, Jones E A, Micetich K C, Young R C, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Int Med 1982; 96: 447–449
   PubMed Web of Science ®Google Scholar
• Wands J R. subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 1975; 2: 979
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Cancer 1996; 78: 2210–2215
   PubMed Web of Science ®Google Scholar
• Wasif Saif M, Little R F, Hamilton J M, Allegra C J, Wilson W H. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann Oncol 2001; 12: 123–129
   PubMed Web of Science ®Google Scholar
• Kohrt H E, Ouyang D L, Keeffe E B. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007; 11: 965
   PubMedGoogle Scholar
• Hui C K, Cheung W W, Au W Y, Lie A K, Zhang H Y, Yueng Y H, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597–1603
   PubMed Web of Science ®Google Scholar
• Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepatitis 2004; 11: 141–147
   PubMed Web of Science ®Google Scholar
• Gutfreund K S, Williams M, George R, Bain V G, Ma M M, Yoshida E M, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000; 33: 469–475
   PubMed Web of Science ®Google Scholar
• Fischer K P, Gutfreund K S, Tyrrell D L. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4: 118–128
   PubMed Web of Science ®Google Scholar
• Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21: 243–253
   PubMed Web of Science ®Google Scholar
• Lai C L, Chien R N, Leung N W, Chang T T, Guan R, Tai D I, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–68
   PubMed Web of Science ®Google Scholar
• Lam K C, Lai C L, Trepo C, Wu P C. Deleterious effect of prednisolone in HbsAg-positive chronic active hepatitis. N Engl J Med 1981; 304: 380–386
   PubMed Web of Science ®Google Scholar
• Cheng A L. Steroid free chemotherapy decreases the risk of hepatitis flare ups in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87: 1202
   PubMed Web of Science ®Google Scholar
• Scullard G H, Smith C I, Mengan T C. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987–991
   PubMed Web of Science ®Google Scholar
• Sagnelh E, Manzillo G, Maho G. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2: 395–397
   PubMed Web of Science ®Google Scholar
• Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Hematol 2005; 74: 158–165
   PubMed Web of Science ®Google Scholar
• Cheng A L, Hsiung C A, Su I J, Chen P J, Chang M C, Tsao C J, et al. Steroid free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320–1328
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627–629
   PubMed Web of Science ®Google Scholar
• Shimizu D, Nomura K, Matsumoto Y, Ueda K, Yamaguchi K, Minami M, et al. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy. World J Gastroenterol 2004; 10: 2301–2302
   PubMed Web of Science ®Google Scholar
• Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721–724
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68–69
   PubMed Web of Science ®Google Scholar